Czechia vs Jordan: Life science patents granted, by technology
Czechia
21 patents
in 2023
Jordan
23 patents
in 2023
Czechia rank
29th
Jordan rank
28th
Life science patents granted, by technology over time
- Czechia
- Jordan
How they compare
Jordan currently reports 23 patents against 21 patents in Czechia, a difference of 2 patents.
That makes Jordan's figure about 1.1 times Czechia's.
The two have swapped places 1 time across 27 shared years of data; in 1995 it was Czechia ahead.
Czechia ranks 29th and Jordan ranks 28th of 65 countries.
Across the 4 decades both report, Czechia averaged higher in 3 and Jordan in 1.
Head to head by decade
| Decade | Czechia | Jordan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 55.25 patents | 3.75 patents | 51.5 patents | Czechia |
| 2000s | 179.33 patents | 8.67 patents | 170.67 patents | Czechia |
| 2010s | 56.9 patents | 11.3 patents | 45.6 patents | Czechia |
| 2020s | 16.75 patents | 63.5 patents | 46.75 patents | Jordan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher life science patents granted, by technology, Czechia or Jordan?
- Jordan, at 23 patents against 21 patents in Czechia as of 2023.
- What is the difference in life science patents granted, by technology between Czechia and Jordan?
- 2 patents, with Jordan ahead.
- How many years of comparable data are there for Czechia and Jordan?
- 27 years are reported by both, from 1995 to 2023.
- How do Czechia and Jordan rank globally for life science patents granted, by technology?
- Czechia ranks 29th and Jordan ranks 28th of 65 countries.
- Where does this data come from?
- World Intellectual Property Organization (WIPO) (2025) β processed by Our World in Data, published as Life science patents granted, by technology. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of pharmaceutical patents granted by the filing office in a given year. Pharmaceutical patents typically cover new drugs, biological treatments or vaccines.